Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

Head and neck cancer affects nearly 750,000 patients, with more than 300,000 deaths annually. Advances in first line surgical treatment have improved survival rates marginally particularly in developed countries, however survival rates for aggressive locally advanced head and neck cancer are still p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Farzaneh Kordbacheh, Camile S. Farah
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	head and neck oncology head and neck squamous cell carcinoma precision medicine molecular therapies targeted therapies clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/df5a93e541f941bcab03629edb0b1449
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df5a93e541f941bcab03629edb0b1449
record_format	dspace
spelling	oai:doaj.org-article:df5a93e541f941bcab03629edb0b14492021-11-11T15:33:35ZCurrent and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma10.3390/cancers132154712072-6694https://doaj.org/article/df5a93e541f941bcab03629edb0b14492021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5471https://doaj.org/toc/2072-6694Head and neck cancer affects nearly 750,000 patients, with more than 300,000 deaths annually. Advances in first line surgical treatment have improved survival rates marginally particularly in developed countries, however survival rates for aggressive locally advanced head and neck cancer are still poor. Recurrent and metastatic disease remains a significant problem for patients and the health system. As our knowledge of the genomic landscape of the head and neck cancers continues to expand, there are promising developments occurring in molecular therapies available for advanced or recalcitrant disease. The concept of precision medicine is underpinned by our ability to accurately sequence tumour samples to best understand individual patient genomic variations and to tailor targeted therapy for them based on such molecular profiling. Not only is their purported response to therapy a factor of their genomic variation, but so is their inclusion in biomarker-driven personalised medicine therapeutic trials. With the ever-expanding number of molecular druggable targets explored through advances in next generation sequencing, the number of clinical trials assessing these targets has significantly increased over recent years. Although some trials are focussed on first-line therapeutic approaches, a greater majority are focussed on locally advanced, recurrent or metastatic disease. Similarly, although single agent monotherapy has been found effective in some cases, it is the combination of drugs targeting different signalling pathways that seem to be more beneficial to patients. This paper outlines current and emerging molecular therapies for head and neck cancer, and updates readers on outcomes of the most pertinent clinical trials in this area while also summarising ongoing efforts to bring more molecular therapies into clinical practice.Farzaneh KordbachehCamile S. FarahMDPI AGarticlehead and neck oncologyhead and neck squamous cell carcinomaprecision medicinemolecular therapiestargeted therapiesclinical trialsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5471, p 5471 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	head and neck oncology head and neck squamous cell carcinoma precision medicine molecular therapies targeted therapies clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	head and neck oncology head and neck squamous cell carcinoma precision medicine molecular therapies targeted therapies clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Farzaneh Kordbacheh Camile S. Farah Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
description	Head and neck cancer affects nearly 750,000 patients, with more than 300,000 deaths annually. Advances in first line surgical treatment have improved survival rates marginally particularly in developed countries, however survival rates for aggressive locally advanced head and neck cancer are still poor. Recurrent and metastatic disease remains a significant problem for patients and the health system. As our knowledge of the genomic landscape of the head and neck cancers continues to expand, there are promising developments occurring in molecular therapies available for advanced or recalcitrant disease. The concept of precision medicine is underpinned by our ability to accurately sequence tumour samples to best understand individual patient genomic variations and to tailor targeted therapy for them based on such molecular profiling. Not only is their purported response to therapy a factor of their genomic variation, but so is their inclusion in biomarker-driven personalised medicine therapeutic trials. With the ever-expanding number of molecular druggable targets explored through advances in next generation sequencing, the number of clinical trials assessing these targets has significantly increased over recent years. Although some trials are focussed on first-line therapeutic approaches, a greater majority are focussed on locally advanced, recurrent or metastatic disease. Similarly, although single agent monotherapy has been found effective in some cases, it is the combination of drugs targeting different signalling pathways that seem to be more beneficial to patients. This paper outlines current and emerging molecular therapies for head and neck cancer, and updates readers on outcomes of the most pertinent clinical trials in this area while also summarising ongoing efforts to bring more molecular therapies into clinical practice.
format	article
author	Farzaneh Kordbacheh Camile S. Farah
author_facet	Farzaneh Kordbacheh Camile S. Farah
author_sort	Farzaneh Kordbacheh
title	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
title_short	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
title_full	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
title_fullStr	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
title_full_unstemmed	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
title_sort	current and emerging molecular therapies for head and neck squamous cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/df5a93e541f941bcab03629edb0b1449
work_keys_str_mv	AT farzanehkordbacheh currentandemergingmoleculartherapiesforheadandnecksquamouscellcarcinoma AT camilesfarah currentandemergingmoleculartherapiesforheadandnecksquamouscellcarcinoma
_version_	1718435214433189888

Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

Ejemplares similares